Welcome to our dedicated page for MBII news (Ticker: MBII), a resource for investors and traders seeking the latest updates and insights on MBII stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect MBII's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of MBII's position in the market.
Marrone Bio Innovations (NASDAQ: MBII) announced the retirement of President and CFO James Boyd after seven years. A national search for his replacement is underway, with Boyd continuing in his role until then. CEO Kevin Helash praised Boyd for his leadership during the company's growth in the agricultural biologicals sector. Boyd expressed confidence in the firm’s future, highlighting recent revenue growth and margin expansion, aiming to deliver meaningful shareholder value.
Marrone Bio Innovations (NASDAQ: MBII) has signed an exclusive distribution agreement with Rizobacter for a foliar fertilizer and plant health technology across Argentina, Uruguay, Paraguay, and Bolivia. This partnership aims to enhance crop yield, addressing the growing demand for biologicals in South America, projected to reach USD 1 billion with an 11% CAGR. Rizobacter, with over 43 years of experience, leverages its strong distribution network to introduce MBI's patented technology in the region. The product launch is anticipated in October 2020.
Marrone Bio Innovations, a leader in sustainable bioprotection solutions, will present at the H.C. Wainwright 22nd Annual Global Investment Conference from September 14 to 16, 2020. CFO Jim Boyd will host a virtual presentation on September 14 at 11:30 a.m. ET, followed by one-on-one meetings with CEO Kevin Helash. Interested parties can access the live audio webcast at this link. The company focuses on innovative biological products for crop protection and has a strong patent portfolio.
Marrone Bio Innovations (NASDAQ: MBII) announced its participation in the LD 500 virtual investor conference from September 1-4, 2020. CFO Jim Boyd will present on September 2 at 1:20 PM ET, followed by one-on-one meetings with CEO Kevin Helash. The conference aims to connect growth-oriented companies with investors. Marrone Bio focuses on sustainable bioprotection and plant health solutions, having screened over 18,000 microorganisms and 350 plant extracts, resulting in a robust product portfolio backed by over 400 patents.
Marrone Bio Innovations (NASDAQ: MBII) has partnered with Vive Crop Protection to launch innovative crop protection products. The first product, AZterknot™ FC, combines Reynoutria extract and azoxystrobin, targeting broad crop use in the U.S. This product aims to enhance disease control and plant health. The Allosperse Delivery System integrated into AZterknot FC improves product handling. Regulatory approval is expected in mid-2021, with plans for marketing to specialty crop growers. This collaboration emphasizes MBI's focus on growth through integrated crop management solutions.
Marrone Bio Innovations (NASDAQ: MBII) will present at the Canaccord Genuity 40th Annual Growth Conference from August 11 to 13, 2020. CFO Jim Boyd is set to lead a presentation on August 12 at 4:30 PM Eastern Time, followed by one-on-one meetings with CEO Kevin Helash. The company focuses on sustainable agricultural solutions, boasting over 400 patents and an innovative product line aimed at enhancing crop protection and health. More details can be found on their website.
Marrone Bio Innovations Inc. (NASDAQ: MBII) will release its financial results for the second quarter ending June 30, 2020, on August 10, 2020, after market close. The company also announced the start of Kevin Helash as Chief Executive Officer on August 3, 2020. A conference call will be held on the same day at 1:30 p.m. PT (4:30 p.m. ET) to discuss the financial results and provide updates. Participants can join via U.S. or international dial-in numbers or by webcast. The call will be available for replay through September 10, 2020.
Marrone Bio Innovations (NASDAQ: MBII) appointed Kevin Helash as its new CEO effective August 1, 2020, pending residency approval. Helash, a veteran with over 28 years in agriculture, previously led Agrinos AS through significant restructuring. He replaces founder Dr. Pamela Marrone, who will stay on as a non-employee director. Chairman Bob Woods expressed confidence in Helash's experience to enhance revenue, margins, and cost management, aiming for profitability. The company is recognized for sustainable agricultural solutions, with numerous innovative products and a broad patent portfolio.
Marrone Bio Innovations (NASDAQ: MBII) announced that its biofungicide, Regalia, commands over 25% market share in California's foliar biofungicide segment, despite a 14% overall market decline in early 2020. Stargus, another biofungicide, also received positive feedback from growers following its approval in January 2020. The company noted increased demand for both products, particularly in wine grapes and stone fruits. Regalia and Stargus are exempt from maximum residue limits and are compliant with organic standards.
Marrone Bio Innovations (NASDAQ: MBII) announced on June 22, 2020, that it has regained compliance with Nasdaq's minimum bid price requirement, as confirmed in a notice received on June 19, 2020. CEO Pam Marrone expressed satisfaction with the resolution and emphasized the company's commitment to drive growth and enhance shareholder value moving forward. Marrone Bio is known for its innovative biological products aimed at sustainable agriculture and has a significant portfolio supported by over 400 patents.
FAQ
What is the market cap of MBII (MBII)?
